GlobeNewswire Inc.··Hagens BermanuniQure Stock Collapses 49% Amid FDA Dispute; Class Action Lawsuit Seeks Lead Plaintiffs
uniQure stock plunged 49% after FDA disagreement on gene therapy trial design. Investors with losses eligible to join class action lawsuit by April 2026.
QUREstock declineinvestor losses